Citi reiterates its “Buy” rating on Divi’s Laboratories and sets a target price of Rs 11,700, according to NDTV. The brokerage’s view centers on Divi’s manufacturing capabilities and potential benefits from expanding demand for peptide-based therapies.
Citi highlights that Divi’s has an integrated and cost-efficient peptide manufacturing platform. The argument is that this positioning could help the company support growth as new peptide-oriented treatments gain traction, including developments linked to oral “Wegovy,” as referenced in the coverage. While the outlet focuses on the price target and upside framing, the core company-specific premise cited is Divi’s operational strength in peptide production.
Across the provided sources, the emphasis remains consistent: the rating, the target price, and the manufacturing platform thesis related to peptide demand and oral therapy developments. No other differing viewpoints or additional catalysts are included in the excerpts beyond Citi’s assessment.
